Comparative Pharmacology
Head-to-head clinical analysis: TOPAMAX versus ZONISADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOPAMAX versus ZONISADE.
TOPAMAX vs ZONISADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antiepileptic; modulates voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
Zonisamide is a sulfonamide anticonvulsant. Its precise mechanism of action is unknown, but it is believed to inhibit voltage-sensitive sodium channels and reduce T-type calcium currents, thereby stabilizing neuronal membranes and suppressing neuronal hypersynchronization. It may also modulate GABA and glutamate neurotransmission.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg weekly to effective dose; usual maintenance dose 200-400 mg/day divided twice daily; maximum 1600 mg/day.
100-200 mg orally every 8 hours; maximum 600 mg/day.
None Documented
None Documented
Terminal elimination half-life is 21 hours (range 18-23 hours). Linear pharmacokinetics. Half-life is prolonged in renal impairment (CrCl <70 mL/min: ~35 hours).
Terminal elimination half-life: 63-69 hours in adults; allows once-daily dosing; steady-state achieved in 14-21 days
Renal: ~70% (unchanged drug); remainder as metabolites. Biliary/fecal: minimal (<5%).
Renal: approximately 62% (35% unchanged, 27% as glucuronide conjugate); fecal: 3%; biliary: negligible
Category C
Category C
Anticonvulsant
Anticonvulsant